Results 41 to 50 of about 569,881 (316)

SnapShot: Acute Myeloid Leukemia

open access: yesCancer Cell, 2012
20%-25% (28%-35%); High blast count; Poor prognosisespecially in cases with high mutant to WT allelic ratio5%-7% (10%-14%); Prognostic impact remains controversial10% (9%-14%); Enriched in CBF AML; Prognosis ...
Zeisig, Bernd B.   +3 more
openaire   +2 more sources

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

open access: yesBlood, 2019
Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance.
C. Dinardo   +15 more
semanticscholar   +1 more source

Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells

open access: yesHaematologica, 2018
Acute myeloid leukemia is a disorder characterized by abnormal differentiation of myeloid cells and a clonal proliferation derived from primitive hematopoietic stem cells.
Dang Wu   +13 more
doaj   +1 more source

Congenital acute myeloid leukemia with unique translocation t(11;19)(q23;p13.3) [PDF]

open access: yes, 2015
Congenital leukemia is rarely encountered in clinical practice, even in tertiary children's hospitals. Leukemia may cause significant coagulopathy, putting the patient at risk of intracranial hemorrhage.
Bandt, S. Kathleen   +8 more
core   +3 more sources

Low expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia

open access: yesTumor Biology, 2017
Dysregulation of NKD1 has been identified in several solid tumors. However, the status of NKD1 expression and its clinical implication in acute myeloid leukemia remain largely elusive.
Jing-dong Zhou   +10 more
doaj   +1 more source

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

open access: yesHaematologica, 2018
Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential of IDH1/2 mutations as targets for minimal residual disease assessment in acute myeloid leukemia ...
Yann Ferret   +14 more
doaj   +1 more source

CREB is a critical regulator of normal hematopoiesis and leukemogenesis [PDF]

open access: yes, 2008
The cAMP-responsive element binding protein (CREB) is a 43-kDa nuclear transcription factor that regulates cell growth, memory, and glucose homeostasis. We showed previously that CREB is amplified in myeloid leukemia blasts and expressed at higher levels
Akashi   +55 more
core   +3 more sources

Acute Myeloid Leukemia and Acute Promyelocytic Leukemia

open access: yesHematology, 2003
AbstractThe therapeutic approach to the patient with acute myeloid leukemia (AML) currently evolves toward new frontiers. This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as
Bob, Löwenberg   +2 more
openaire   +2 more sources

Nutritional and Behavioral Intervention for Long‐Term Childhood Acute Leukemia Survivors With Metabolic Syndrome

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Metabolic syndrome (MetS) is a common complication in survivors of childhood acute lymphoblastic and myeloid leukemia (AL), and a major risk factor for premature cardiovascular disease, type‐2‐diabetes, and metabolic dysfunction‐associated steatotic liver disease (MASLD).
Visentin Sandrine   +10 more
wiley   +1 more source

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

open access: yesHaematologica, 2018
Allogeneic hematopoietic stem cell transplantation is the optimal care for patients with high-risk or intermediate - acute myeloid leukemia. In patients lacking matched sibling donor, haploidentical donors are an option.
Dalila Salvatore   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy